Distinguished in Hypertension

Yingqing L. Feng

Guangzhou, CN 
Distinguished in Hypertension
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Yingqing Feng practices in Guangzhou, China. Feng is rated as a Distinguished expert by MediFind in the treatment of Hypertension. Their top areas of expertise are Hypertension, Coronary Heart Disease, Heart Failure, and Metabolic Syndrome.

Their clinical research consists of co-authoring 117 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 61 articles and participated in 1 clinical trial in the study of Hypertension.

Locations

Guangzhou, China
Other Locations
China
No. 106 Zhongshan 2nd Road, Yuexiu, 510080, China
Shenzhen, 518055, China
State Key Laboratory Of Cardiovascular Disease, Peking Union Medical College, Peking Union Medical College Hospital, Xi'an, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial
Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial
Enrollment Status: Unknown
Publish Date: July 28, 2021
Intervention Type: Drug
Study Phase: Not Applicable
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Enrollment Status: Terminated
Publish Date: December 21, 2017
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

117 Total Publications

Associations Between Hematologic Parameters and All-Cause Death in Individuals With Cardio-Renal-Metabolic Multimorbidity: A National Cohort Study.
Associations Between Hematologic Parameters and All-Cause Death in Individuals With Cardio-Renal-Metabolic Multimorbidity: A National Cohort Study.
Journal: Journal of the American Heart Association
Published: September 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Feng's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile